Novo Nordisk Reports Soaring Revenues Driven by Wegovy, with Anti-Obesity Drug Sales Up 407% in 2023

　　【Pharmaceutical Network Enterprise News】Novo Nordisk, the maker of weight-loss drugs, released its Q4 2023 financial report on Wednesday, surpassing market expectations in terms of revenue. Calculated in Danish kroner, Novo Nordisk's revenue in 2023 increased by 31% to 232.3 billion kroner (approximately $33.7 billion), far exceeding the market's expected 21%. Revenue in the North American region surged by 50%. Operating profit rose by 37% to 102.6 billion kroner, while net profit increased by 51% year-on-year, reaching 83.683 billion Danish kroner.
 

From the perspective of the "contributors" driving significant performance growth, Novo Nordisk's highly anticipated semaglutide has demonstrated strong revenue-generating capabilities. In 2023, this product generated sales of 145.811 billion Danish kroner (21.201 billion US dollars) for the company, representing a year-on-year increase of 88.78% and accounting for 62.78% of total revenue. Notably, the semaglutide injection Wegovy, used for weight management, saw its revenue grow by 407% year-on-year, reaching 31.343 billion Danish kroner (4.557 billion US dollars).
 

The financial report shows that Wegovy has been launched in the United States, Denmark, Norway, Germany, the United Kingdom, Iceland, Switzerland, and the UAE, with the market size expanding by 116% compared to 2022. Industry insiders predict that sales of Wegovy will continue to grow. Evaluate forecasts that the drug's sales will reach nearly $8 billion in 2024.
 

In addition, Novo Nordisk's GLP-1 drugs for the treatment of type 2 diabetes (Rybelsus, Ozempic, and Vitoza) saw a 48% increase in revenue (in Danish kroner) in 2023, reaching 123.1 billion kroner.
 

With the increasing prevalence of type 2 diabetes and obesity, the demand for related pharmaceuticals will continue to grow. As Eli Lilly launched the weight-loss drug Zepbound in the U.S. at the end of last year, Novo Nordisk will also face direct competition.
 

In response, Novo Nordisk plans to heavily invest in expanding its production capacity. According to company disclosures, it has invested over 16 billion Danish kroner and more than 42 billion Danish kroner to expand its existing production facilities in Chartres, France, and Kalundborg, Denmark, respectively. Relevant company representatives stated that both investments include GLP-1 production capacity, which will enhance Novo Nordisk's ability to meet future demand for innovative products. Additionally, the company mentioned that, aside from construction projects, it has implemented a maximum production schedule operating 24 hours a day, 7 days a week, with three rotating shifts to meet market demand.
 

Since 2024, Novo Nordisk and its competitors have also been making frequent moves in the weight-loss drug market. On January 4, Novo Nordisk announced a significant investment in the research and development of new weight-loss therapies, reaching research collaboration agreements with two American biotech startups, each with a total value of up to $532 million. Meanwhile, Eli Lilly launched a "weight-loss drug delivery to your door" service, allowing obese patients to conveniently receive prescriptions from telehealth providers and have the medication delivered directly to their homes.
 

Another report revealed that in the overseas market, both Novo Nordisk and its competitor Lilly are lobbying for health insurance coverage of their expensive weight-loss drugs. If the lobbying succeeds, Novo Nordisk's sales will also see a radiating growth.
 

Moreover, in the Chinese market, both Novo Nordisk and its competitor Eli Lilly have submitted applications to the National Medical Products Administration (NMPA) for the approval of their products for weight loss. Both applications have been accepted but are yet to be approved for marketing. Some securities firms have stated that the potential of China's weight loss market is enormous, and the progress of these two pharmaceutical companies in obtaining approval in China will have a decisive impact on their competitive edge.
 

For the outlook on 2024 performance, Novo Nordisk predicted that this year will still achieve double-digit sales growth. After adjustment by fixed exchange rates, the expected revenue growth rate is between 18-26%; meanwhile, profit growth is projected at 21-29%.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.